.jpg?#)
Supriya Lifescience Eyes 33-35% Ebitda Margins In FY26 Led By New Products, US Expansion
The company has already launched a new anaesthetic product in the first quarter of FY26, targeting a $300 million market.
The company has already launched a new anaesthetic product in the first quarter of FY26, targeting a $300 million market.
What's Your Reaction?
